171 related articles for article (PubMed ID: 30171222)
1. High-dose Benda-EAM versus BEAM in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation.
Tsang ES; Villa D; Loscocco F; Visani G; Power M; Guiducci B; Clissa C; Song K; Toze C; Abou Mourad Y; Sutherland H; Sanford D; Nantel SH; Sehn LH; Scott DW; Savage KJ; Connors JM; Gerrie AS; Isidori A
Bone Marrow Transplant; 2019 Mar; 54(3):481-484. PubMed ID: 30171222
[No Abstract] [Full Text] [Related]
2. BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant.
Marchesi F; Capria S; Giannarelli D; Trisolini SM; Ansuinelli M; Caputo MD; Serrao A; Gumenyuk S; Renzi D; Pupo L; Palombi F; Provenzano I; Di Rocco A; Pisani F; Romano A; Spadea A; Papa E; Canfora M; Cantonetti M; Mengarelli A
Bone Marrow Transplant; 2018 Aug; 53(8):1051-1054. PubMed ID: 29440737
[No Abstract] [Full Text] [Related]
3. BEAC (carmustine, etoposide, cytarabine, and cyclophosphamide) in autologous hematopoietic cell transplantation: a safe and effective alternative conditioning regimen for Hodgkin and non-Hodgkin lymphoma.
Sakellari I; Gavriilaki E; Bouziana S; Constantinou V; Mallouri D; Vardi A; Marvaki A; Batsis I; Sotiropoulos D; Anagnostopoulos A
Bone Marrow Transplant; 2019 Jun; 54(6):921-923. PubMed ID: 30410083
[No Abstract] [Full Text] [Related]
4.
Conlon KC; Sportes C; Brechbiel MW; Fowler DH; Gress R; Miljkovic MD; Chen CC; Whatley MA; Bryant BR; Corcoran EM; Kurdziel KA; Pittaluga S; Paik CH; Lee JH; Fleisher TA; Carrasquillo JA; Waldmann TA
Cancer Biother Radiopharm; 2020 May; 35(4):249-261. PubMed ID: 32275165
[No Abstract] [Full Text] [Related]
5. BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma.
Singer S; Dean R; Zhao Q; Sharma N; Abounader D; Elder P; Hofmeister CC; Benson DM; Rosko A; Penza S; Andritsos L; Vasu S; Jaglowski S; William BM; Bolwell B; Pohlman B; Kalaycio M; Jagadeesh D; Hill B; Sobecks R; Devine SM; Majhail NS; Efebera YA
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1107-1115. PubMed ID: 30716453
[TBL] [Abstract][Full Text] [Related]
6. A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi.
Olivieri J; Mosna F; Pelosini M; Fama A; Rattotti S; Giannoccaro M; Carli G; Tisi MC; Ferrero S; Sgherza N; Mazzone AM; Marino D; Calimeri T; Loseto G; Saraceni F; Tomei G; Sica S; Perali G; Codeluppi K; Billio A; Olivieri A; Orciuolo E; Matera R; Stefani PM; Borghero C; Ghione P; Cascavilla N; Lanza F; Chiusolo P; Finotto S; Federici I; Gherlinzoni F; Centurioni R; Fanin R; Zaja F;
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1814-1822. PubMed ID: 29857196
[TBL] [Abstract][Full Text] [Related]
7. Prognostic differences between carmustine, etoposide, cytarabine and melphalan (BEAM) and carmustine, etoposide, cytarabine, melphalan and fludarabine (BEAMF) regimens before autologous stem cell transplantation plus chimeric antigen receptor T therapy in patients with refractory/relapsed B-cell non-Hodgkin-lymphoma.
Xin X; Lin L; Yang Y; Wang N; Wang J; Xu J; Wei J; Huang L; Zheng M; Xiao Y; Meng F; Cao Y; Zhu X; Zhang Y
Cytotherapy; 2024 May; 26(5):456-465. PubMed ID: 38385909
[TBL] [Abstract][Full Text] [Related]
8. Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning.
Isidori A; Christofides A; Visani G
Leuk Lymphoma; 2016 Nov; 57(11):2499-509. PubMed ID: 27243412
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
[TBL] [Abstract][Full Text] [Related]
10. Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma.
Grisariu S; Shapira MY; Or R; Avni B
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):272-279. PubMed ID: 29500148
[TBL] [Abstract][Full Text] [Related]
11. Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas.
Sakellari I; Mallouri D; Batsis I; Apostolou C; Konstantinou V; Abela EM; Douka V; Marvaki A; Karypidis K; Iskas M; Baliakas P; Kaloyannidis P; Yannaki E; Sotiropoulos D; Kouvatseas G; Smias C; Anagnostopoulos A
Leuk Lymphoma; 2015; 56(11):3071-81. PubMed ID: 25760637
[TBL] [Abstract][Full Text] [Related]
12. Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study.
Martín A; Caballero MD; Pérez-Simón JA; López-Holgado N; Mateos MV; Cañizo MC; Miguel JF
Bone Marrow Transplant; 2004 Oct; 34(8):675-82. PubMed ID: 15334049
[TBL] [Abstract][Full Text] [Related]
13. High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity.
Noesslinger T; Panny M; Simanek R; Moestl M; Boehm A; Menschel E; Koller E; Keil F
Eur J Haematol; 2018 Sep; 101(3):326-331. PubMed ID: 29799642
[TBL] [Abstract][Full Text] [Related]
14. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
Nieto Y; Thall PF; Ma J; Valdez BC; Ahmed S; Anderlini P; Popat U; Jones RB; Shpall EJ; Hosing C; Qazilbash M; Kebriaei P; Alousi A; Timmons M; Gulbis A; Myers A; Oki Y; Fanale M; Dabaja B; Pinnix C; Milgrom S; Champlin R; Andersson BS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1602-1609. PubMed ID: 29501779
[TBL] [Abstract][Full Text] [Related]
15. Finding the Optimal Conditioning Regimen for Relapsed/Refractory Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation: A Retrospective Comparison of BEAM and High-Dose ICE.
Esbah O; Tekgündüz E; Şirinoğlu Demiriz I; Civriz Bozdağ S; Kaya A; Tetik A; Kayıkçı Ö; Durgun G; Kocubaba Ş; Altuntaş F
Turk J Haematol; 2016 Sep; 33(3):209-15. PubMed ID: 26377357
[TBL] [Abstract][Full Text] [Related]
16. Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol.
Ramzi M; Mohamadian M; Vojdani R; Dehghani M; Nourani H; Zakerinia M; Haghighinejad H
Exp Clin Transplant; 2012 Apr; 10(2):163-7. PubMed ID: 22432762
[TBL] [Abstract][Full Text] [Related]
17. A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM.
Kothari J; Foley M; Peggs KS; Mackenzie S; Thomson K; Morris E; Ardeshna KM; Virchis AE; Linch DC; Lambert J
Bone Marrow Transplant; 2016 Oct; 51(10):1397-1399. PubMed ID: 27214072
[No Abstract] [Full Text] [Related]
18. Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30
Grover NS; Hucks G; Riches ML; Ivanova A; Moore DT; Shea TC; Seegars MB; Armistead PM; Kasow KA; Beaven AW; Dittus C; Coghill JM; Jamieson KJ; Vincent BG; Wood WA; Cheng C; Morrison JK; West J; Cavallo T; Dotti G; Serody JS; Savoldo B
Lancet Haematol; 2024 May; 11(5):e358-e367. PubMed ID: 38555923
[TBL] [Abstract][Full Text] [Related]
19. Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma.
Tseng YD; Stevenson PA; Cassaday RD; Cowan A; Till BG; Shadman M; Graf SA; Ermoian R; Smith SD; Holmberg LA; Press OW; Gopal AK
Biol Blood Marrow Transplant; 2018 Feb; 24(2):282-287. PubMed ID: 29061536
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
Flowers CR; Costa LJ; Pasquini MC; Le-Rademacher J; Lill M; Shore TB; Vaughan W; Craig M; Freytes CO; Shea TC; Horwitz ME; Fay JW; Mineishi S; Rondelli D; Mason J; Braunschweig I; Ai W; Yeh RF; Rodriguez TE; Flinn I; Comeau T; Yeager AM; Pulsipher MA; Bence-Bruckler I; Laneuville P; Bierman P; Chen AI; Kato K; Wang Y; Xu C; Smith AJ; Waller EK
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1197-1205. PubMed ID: 27040394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
